Diazoxide and N omega-nitro-L-arginine counteracted A beta 1-42-induced cytotoxicity

Guozhao Ma1, Shengdi Chen

  • 1Department of Neurology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China.

Neuroreport
|July 17, 2004
PubMed

Insights

Diazoxide, a K(+) channel opener, protects neurons from amyloid-beta toxicity by preventing mitochondrial dysfunction and reactive oxygen species generation. These protective effects occur before significant cell apoptosis, indicating early intervention potential.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • K(+) channel openers are known to protect cultured neurons from excitotoxicity.
  • Amyloid-beta (A beta(1-42)) is implicated in neurodegenerative diseases and can induce neuronal damage.

Purpose of the Study:

  • To investigate the neuroprotective effects of diazoxide, a K(+) channel opener, against A beta(1-42)-induced toxicity.
  • To explore the role of mitochondrial membrane potential and reactive oxygen species (ROS) in A beta(1-42)-induced neuronal damage.

Main Methods:

  • Utilized diazoxide as a K(+) channel opener.
  • Administered A beta(1-42) to cultured neurons.
  • Measured mitochondrial membrane potential and intracellular ROS levels.
  • Assessed the impact of N omega-nitro-L-arginine, an inducible nitric oxide synthase inhibitor.

Main Results:

  • Diazoxide protected cells from A beta(1-42)-induced increases in mitochondrial membrane potential and ROS levels.
  • N omega-nitro-L-arginine also protected cells against these A beta(1-42)-induced changes.
  • A 24-hour exposure to A beta(1-42) did not induce apoptosis, suggesting that mitochondrial dysfunction and ROS increase precede cell death.

Conclusions:

  • Diazoxide exhibits neuroprotective properties against A beta(1-42) toxicity.
  • Mitochondrial membrane potential and ROS generation are early events in A beta(1-42)-induced neuronal injury.
  • Targeting these early events may offer therapeutic strategies for neurodegenerative conditions.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...